Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Overview
Know Labs Inc is a cutting-edge medical diagnostic company that specializes in the development of non-invasive testing technologies using proprietary Bio-RFID and ChromaID systems. These technologies leverage electromagnetic energy to capture the unique signature of substances, enabling the detection and identification of biomarkers without the need for conventional invasive procedures. By driving innovation in the field of healthcare diagnostics, Know Labs is committed to providing alternatives that enhance patient experience and streamline clinical operations.
Core Technologies and Innovations
Know Labs Inc has developed two main technologies that define its product offerings:
- Bio-RFID Technology: This technology uses electromagnetic signals to record distinct bio-signatures from various substances, allowing for accurate identification and authentication. It offers a non-invasive approach, minimizing discomfort while delivering precise diagnostic information.
- ChromaID Technology: Utilizing advanced spectral analysis, ChromaID captures the chromatic signature of materials, facilitating their detection and verification in a manner that bypasses traditional, more invasive methods.
These innovations not only represent significant advancements in diagnostic testing but also hold the potential to redefine standard practices within the medical field.
Applications in Medical Diagnostics
The technologies developed by Know Labs Inc are applicable to a wide range of diagnostic scenarios. A primary focus is on the development of wearable devices that integrate these technologies, such as non-invasive blood glucose monitors. This approach aims to eliminate the need for traditional fingerstick testing, thereby reducing patient discomfort and improving adherence to monitoring regimens. The practical applications of such tools extend beyond diabetes management to potentially encompass a variety of diagnostic uses where traditional methods are cumbersome or invasive.
Market Position and Industry Context
Operating in the competitive healthcare technology and medical diagnostics sector, Know Labs Inc carves out its niche by offering significantly disruptive non-invasive testing methods. Its emphasis on using electromagnetic energy to capture biomolecular signatures sets the company apart from traditional lab-based diagnostic systems. In doing so, Know Labs not only addresses critical challenges such as patient discomfort and procedural inefficiencies but also reinforces its position as a specialist in innovative diagnostic solutions within a rapidly evolving market.
Business Model and Revenue Considerations
The company’s business model centers on the research, development, and commercialization of its proprietary diagnostic technologies. Revenue generation is primarily achieved through the sales and marketing of medical devices and integrated diagnostic systems, along with potential licensing of its technologies to strategic partners. This model allows Know Labs Inc to expand the reach of its innovations throughout various segments of the healthcare industry, further solidifying its role as a transformative force in diagnostics.
Competitive Advantages and Industry Impact
Know Labs Inc distinguishes itself through its commitment to non-invasive, patient-friendly diagnostics. The use of sophisticated electromagnetic energy-based techniques provides an alternative to traditional, often cumbersome laboratory tests. This focus on innovation not only improves the accuracy and speed of diagnosis but also positions the company as a thought leader in the development of next-generation medical devices. The combination of its unique technologies and a strategically diversified product portfolio has the potential to influence the broader healthcare landscape significantly.
Detailed Technological and Clinical Insights
Understanding the technical nuances of Know Labs Inc's offerings requires an appreciation of both the scientific and practical aspects of its technologies. The Bio-RFID system relies on a precise interaction between electromagnetic waves and biological tissues, capturing signatures that are both unique and replicable. Similarly, the ChromaID system applies principles of spectral analysis to differentiate between subtle variations in material composition. Together, these systems exemplify how advanced technology can be harnessed to solve persistent challenges in clinical diagnostics. The integration of these innovations into wearable devices is poised to offer a practical, everyday application that can change how routine health monitoring is conducted.
Know Labs (NYSE American: KNW) announced that NYSE American has accepted its compliance plan on December 10, 2024. The company has been granted until March 27, 2026 to regain compliance with the exchange's listing standards under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide. During this period, KNW will undergo periodic reviews to assess progress with the plan's initiatives. The company's shares will continue trading on NYSE American, subject to meeting other listing requirements. If KNW fails to regain compliance by the deadline or show sufficient progress, NYSE American may initiate delisting proceedings. This development doesn't affect KNW's business operations or SEC reporting obligations.
Know Labs (NYSE American: KNW) released its FY2024 10-K annual report, addressing shareholder concerns about its going concern audit opinion. The company reported a $16 million net loss, including $5 million in non-cash charges. Key achievements include: development of 2nd generation KnowU™ CGM, completion of companion mobile app, filing of 68 new patents (total 332 active patents), and clinical studies showing 93% accuracy in glycemic level determination. The company reduced monthly cash burn by 42% to $700,000 and initiated strategic projects including a Smart Steering Wheel initiative. Management expressed confidence in accessing capital through their effective S-3 shelf offering to continue operations.
Know Labs (NYSE American: KNW) announced that its audited financial statements for the fiscal year ended September 30, 2024, received an audit opinion containing a going concern explanation from its independent registered public accounting firm. This disclosure, previously included in the company's Annual Report on Form 10-K filed on November 14, 2024, raises questions about the company's ability to continue operations. The announcement complies with NYSE American Company Guide Section 610(b) requirements and does not represent any changes to the company's financial statements or Annual Report.
Know Labs (NYSE: KNW) reported its FY2024 financial results, showing a net loss of $16.58 million, an 8.4% increase from FY2023's loss of $15.29 million. The company's EPS loss improved to $0.20 from $0.41 in FY2023. R&D expenses decreased 21% to $6.11 million, while SG&A expenses increased to $9.11 million. Cash position declined to $3.11 million from $8.02 million year-over-year. The company expects its current cash to sustain operations through February 28, 2025, and plans to raise additional funds through equity, preferred stock, and convertible debentures.
Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive diagnostics technology, has announced two key additions to its executive leadership team. John Cronin joins as Interim Chief Technology Officer, bringing extensive experience in intellectual property strategy and patent development. Dominic Klyve, Ph.D., becomes Chief Science Officer, tasked with leading the research and development team in building the first non-invasive glucose monitor.
These appointments aim to accelerate platform development and secure multiple strategic partnerships. Cronin, previously a board member and strategic advisor, will oversee product development and technology strategy. Klyve, a former lead data scientist at Know Labs, brings significant research experience and has authored several studies for the company.
The expanded leadership team is expected to drive technology development and assist in bringing Know Labs' platform to market through strategic relationships with global leaders in med tech, pharma, and consumer markets.
Know Labs (NYSE: KNW) has engaged The Stanbridge Group to establish a strategic partnership with an automotive OEM to integrate its non-invasive sensor technology into steering wheels. Initial lab tests show the sensor can detect blood alcohol levels non-invasively, potentially preventing impaired driving. This innovation emerged during the development of their glucose monitoring tech, leading to a patent filing in 2022, published in 2024 (US 2024/0050007 A1). The 2021 Infrastructure Investment and Jobs Act mandates passive alcohol detection systems in new vehicles by 2026, aligning with Know Labs' technology. CEO Ron Erickson highlighted the broad applications of their technology, including driver health and wellness. In 2022, drunk driving caused 13,524 deaths in the US, prompting NHTSA to propose rules for impaired driving prevention tech. Rick Stanbridge of The Stanbridge Group emphasized the sensor's potential to address manufacturers' and NHTSA's concerns. Further details are available at www.knowlabs.co.
Know Labs, Inc. (NYSE American: KNW) has received a notice of noncompliance with NYSE American continued listing standards. The company fails to meet the stockholders' equity requirements set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Know Labs must submit a compliance plan by October 27, 2024, outlining how it intends to regain compliance by March 27, 2026.
The notice does not immediately impact the listing of Know Labs' common stock, which will continue to trade under the symbol "KNW" with an added ".BC" designation. The company is preparing its plan based on expected business progress and technological developments, including potential announcements regarding strategic and joint venture partnerships. However, there is no guarantee that Know Labs will achieve compliance within the required timeframe.
Know Labs, Inc. (NYSE American: KNW) announced the publication of its peer-reviewed study in IEEE Sensors Journal, titled 'Non-Invasive Blood Glucose Measurement Using RF Spectroscopy and a lightGBM AI Model'. The study validates the novelty of Know Labs' proprietary radiofrequency (RF) dielectric sensor for non-invasive blood glucose monitoring.
Key points:
- Know Labs' technology uses broadband dielectric spectroscopy, scanning a large range of RF frequencies
- The approach enables the use of thousands of data points for measurement, surpassing traditional resonance techniques
- Results from a first-generation device study were initially announced in May 2023
- Know Labs has since published studies showing improved accuracy in clinical research protocols
- The company is progressing towards FDA clearance with ongoing clinical and bench studies
Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive medical diagnostic technology, has announced a $1.655 million public offering. The company is selling 6,365,385 units at $0.26 per unit, with each unit comprising one common stock share and one warrant to purchase an additional share at $0.26. The offering closed on August 15, 2024.
The net proceeds will be used for product development, clinical studies, general and administrative expenses, intellectual property, and working capital. Boustead Securities, and The Benchmark Company, acted as advisors, receiving a 5% cash fee and warrants for 636,538 common stock shares. The offering is made under Know Labs' effective shelf registration statement on Form S-3.
Know Labs, Inc. (NYSE American: KNW) reported Q3 FY 2024 financial results, showing a net loss of $4.10 million, up 13.9% from Q3 FY 2023. Earnings per share improved to a loss of $0.05 from $0.07 last year. R&D expenses decreased by 28.2% to $1.35 million, while SG&A expenses increased to $2.49 million. The company's cash position decreased to $2.13 million from $8.02 million at the end of FY 2023. Know Labs closed a $3.45 million public offering in August 2024, expecting to fund operations until at least December 31, 2024. The company plans to seek additional funding to ensure operations into 2025 and is taking steps to address negative shareholder equity through debt conversion.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
What core technologies power Know Labs Inc's diagnostic solutions?
How do Know Labs' technologies improve patient care?
What is the primary business focus of Know Labs Inc?
In which industry does Know Labs Inc operate?
How does Know Labs differentiate itself from traditional diagnostic methods?
What potential applications arise from Know Labs' wearable diagnostic technology?
